我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

苯那普利对充血性心力衰竭患者神经内分泌激素水平的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
1998年第4期
页码:
211-212,214
栏目:
论著
出版日期:
1998-07-01

文章信息/Info

Title:
Effects of benazepril on neurocrine levels in patients with congestive heart failure
作者:
马建林1ⅹ 毛焕元2ⅹⅹ 周本财2 胡 佳2
1海南省人民医院心内科 海口 570311 2同济医科大学心血管病研究所
Author(s):
Ma Jianlin1; Mao Huanyuan2; Zhou Bencai2; Hu Jia2
1Hospital of Hainan Province，Haikou 570311 2Institute of Cardiovascular Disease，Tongji Medical University，Wuhan 430022
关键词:
苯那普利 心力衰竭; 充血性神经内分泌激素
Keywords:
benazepril heart failure; congestive neurocrine
分类号:
-
DOI:
-
文献标识码:
-
摘要:
作者对38例充血性心力衰竭(CHF)患者采用苯那普利治疗4周，观察其治疗前后血浆肾素活性(PRA)、血管紧张素Ⅱ(Ang Ⅱ)、醛固酮(ALD)、去甲肾上腺素(NE)、肾上腺素(E)、血栓素B2(TXB2)及6-酮-前列腺素Ff12(6-keto-PGF1a)水平的变化情况，发现治疗后患者PRA，Ang Ⅱ，ALD，NE，E，TXB2水平均显著下降，而6-keto-PGF1a水平明显升高，并且服药后心功能改善总有效率达84.2％。结果提示苯那普利不仅能抑制CHF患者肾素血管紧张素系统活性，而且还能抑制交感神经系统活性、调节前列腺素代谢，改善患者的病情。
Abstract:
38 patients with congestive heart failure were treated with benazepril for 4 weeks.Before and after the treatment，levels of blood plasma renin activity(PRA)，angiotensinⅡ(AngⅡ)，aldosterone(ALD)，norepinephrine(NE)，epinephrine(E)，thromboxane B2(TXB2)and 6-Keto-prostaglandin F1a(6-Keto-PGF1a)were measured in a11 patients．The results showed that levels of PRA，AngⅡ，ALD，NE，E，TXB2 significantly decreased and those of 6-Keto-PGF1asignificantly increased after the treatment of the 38 cases in the treatment group，32(84.2 ％)responded to the medicine and gained improvement in cardiac function．The results suggested that benazepril is prominently effective in suppressing activities of renin—angiotensin and sympathetics ystem，in regulating metabolism of prostaglandins and in relieving symptoms of the patients．

参考文献/References

［1］Tan LB, Jalil JE, Janicki JS, et al. Cardiotoxic effects of angiotension Ⅱ. J Am Coll Cardiol, 1989; 13: 13: 2A.

［2］Builope LM , Mirarda B. Oliet A , et al. Control of hypertension with angiotensin-converting enzyme inhibitor captopril reduces glomeralar proteinuia. J Hypertens, 1988; 4 (Supp l) : 467.

［3］陈灏珠. 血管紧张素转化酶抑制剂临床应用的评价. 中国医学杂志, 1995; 75: 67.

［4］Thurston H. Angiotensin coverting enzyme inhibitor as first-line treatment for hypertension. Clin Exp Pharmacol, 1992; 19(Supp l) : 16.

［5］Balfour JA , Goa KL. Benazepril, A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drug s, 1991; 42: 511.

［6］Hason JF, Tingsted L , Pasmussen V , et al. Verapamil and angiotensin-converting enzyme inhibitors in patients with coronary artery disease and reduced left ventricular ejection fraction. Am J Cardiol, 1996; 77: 167.

备注/Memo

备注/Memo:
(收稿1997-12-22　修回1998-06-01)ⅹ博士研究生 ⅹⅹ导师
更新日期/Last Update: 1998-07-01